Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

Ligand-induced movements of inner transmembrane helices of
Glut1 revealed by chemical cross-linking of di-cysteine mutants
Mike Mueckler
Washington University School of Medicine in St. Louis

Carol Makepeace
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Mueckler, Mike and Makepeace, Carol, ,"Ligand-induced movements of inner transmembrane helices of
Glut1 revealed by chemical cross-linking of di-cysteine mutants." PloS One. 7,2. 1-11. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1023

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Ligand-Induced Movements of Inner Transmembrane
Helices of Glut1 Revealed by Chemical Cross-Linking of
Di-Cysteine Mutants
Mike Mueckler*, Carol Makepeace
The Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract
The relative orientation and proximity of the pseudo-symmetrical inner transmembrane helical pairs 5/8 and 2/11 of Glut1
were analyzed by chemical cross-linking of di-cysteine mutants. Thirteen functional di-cysteine mutants were created from a
C-less Glut1 reporter construct containing cysteine substitutions in helices 5 and 8 or helices 2 and 11. The mutants were
expressed in Xenopus oocytes and the sensitivity of each mutant to intramolecular cross-linking by two homobifunctional
thiol-specific reagents was ascertained by protease cleavage followed by immunoblot analysis. Five of 9 mutants with
cysteine residues predicted to lie in close proximity to each other were susceptible to cross-linking by one or both reagents.
None of 4 mutants with cysteine substitutions predicted to lie on opposite faces of their respective helices was susceptible
to cross-linking. Additionally, the cross-linking of a di-cysteine pair (A70C/M420C, helices 2/11) predicted to lie near the
exoplasmic face of the membrane was stimulated by ethylidene glucose, a non-transported glucose analog that
preferentially binds to the exofacial substrate-binding site, suggesting that the binding of this ligand stimulates the closure
of helices at the exoplasmic face of the membrane. In contrast, the cross-linking of a second di-cysteine pair (T158C/L325,
helices 5/8), predicted to lie near the cytoplasmic face of the membrane, was stimulated by cytochalasin B, a glucose
transport inhibitor that competitively inhibits substrate efflux, suggesting that this compound recruits the transporter to a
conformational state in which closure of inner helices occurs at the cytoplasmic face of the membrane. This observation
provides a structural explanation for the competitive inhibition of substrate efflux by cytochalasin B. These data indicate
that the binding of competitive inhibitors of glucose efflux or influx induce occluded states in the transporter in which
substrate is excluded from the exofacial or endofacial binding site.
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12 transmembrane helix model for Glut1 is also strongly
supported by the deduced structures of the lac permease [15],
the glycerol-3-P antiporter [17], the fucose transporter [16], and
the EmrD multidrug transporter [18], all members of the MFS
expressed in E. coli. These 4 bacterial transporters share a
common folding pattern, despite the fact that they share little if
any sequence identity. Several of the twelve proposed transmembrane segments of Glut1 were originally predicted to form
amphipathic alpha-helices, an observation which led to the
hypothesis that these helices form the walls of a water-filled cavity
involved in the binding and subsequent transfer of glucose across
the membrane [7]. It was also suggested that hydroxyl- and amidecontaining amino acid side chains within the transmembrane
helices form the sugar-binding site of Glut1 via hydrogen bonding
with glucose hydroxyl groups.
Considerable experimental support has accumulated for this
basic structural model. Cysteine-scanning mutagenesis and
substituted cysteine accessibility studies implicate transmembrane
segments 1 [21], 2 [22], 5 [23], 7 [22,24], 8 [25], 10 [26], and 11
[27] of Glut1 in the formation of a water-accessible cleft within the
membrane. In contrast, helices 3 [28], 6 [29], 9 [30], and 12 [31]

Introduction
The passive exchange of glucose across the membranes of
animal cells is mediated by members of the GLUT (SLC2a)
protein family (reviewed in [1,2,3]). The GLUT family belongs to
the Major Facilitator Superfamily (MFS), the largest category of
proteins involved in the transport of small molecules across
membranes [4,5]. Glut1, the prototype member of the GLUT
family and the first eukaryotic member of the MFS Superfamily to
be identified and cloned [6,7], is one of the most extensively
studied of all membrane transporters [8]. Kinetic and biophysical
studies of glucose transport in the human red blood cell are mostly
consistent with an alternating conformation mechanism
[9,10,11,12,13] but see [12,14]), a conclusion that is consistent
with high-resolution structural studies of 4 bacterial MFS proteins
[15,16,17,18].
Glut1 was the first transporter predicted to possess 12
transmembrane helices [7], a feature that it appears to share with
the vast majority of MFS transporters [4]. This prediction has
been confirmed by glycosylation-scanning mutagenesis experiments [19] and other biochemical analyses (reviewed in [20]). The
PLoS ONE | www.plosone.org
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appear to have limited access to the external solvent, suggesting
that these segments form the outer stabilizing helices as indicated
by the known bacterial MFS structures [15,16,17,18]. Transmembrane segment 4 of Glut1 does not appear to react with pCMBS
added to the external solvent [32]. This transmembrane segment is
predicted to be an inner helix in the outward-facing conformation
of the fucose transporter, indicating that one face should be
accessible to the external solvent [16]. Thus, either the two
structures differ or reaction of helix 4 with pCMBS cannot be
detected in Glut1 for structural reasons that are unclear at present.
Gln161 within helix 5 [33] and Gln282 within helix 7 [34] appear to
participate in forming the exofacial substrate-binding site. Val165,
which is positioned one helical turn distant from Glu161, is
accessible to aqueous sulfhydryl reagents and appears to lie near
the exofacial substrate binding site based on mutagenesis and
inhibitor studies [35]. An aromatic side-chain at position 412
within helix 11 appears to be essential for transport activity [20].
Additionally, hydrogen exchange studies demonstrate that 30% of
peptide hydrogen atoms are exposed to water in purified,
reconstituted Glut1, consistent with their role in the formation of
an aqueous cleft in the membrane [36]. Little is known, however,
about movements of specific helices in Glut1 that occur during the
transport cycle or after the binding of ligands.
In the present study we utilized chemical cross-linking of dicysteine (di-C) Glut1 mutants constructed in a reporter molecule
to determine the relative orientation and proximity of transmembrane helices 5/8 and 2/11. Both pairs of helices are predicted
to comprise a part of the inner helical bundle that forms the
outward-facing aqueous cavity [30] and appear to lie within ,6 Å
of each other throughout much of their lengths, suggesting that
they lie roughly parallel to each other in at least one
conformational state. Additionally, the binding of a nontransported exofacial ligand, ethylidene glucose, promoted the
closure of helices 2 and 11 at the exoplasmic face of the
membrane. In contrast, cytochalasin B recruited Glut1 to a
conformation in which helices 5 and 8 close at the cytoplasmic face
of the membrane. This latter observation provides the first data
concerning the relative movement of specific helices and pairs of
amino acid residues of Glut1 induced by cytochalasin B binding,
and provides a possible explanation for the competitive inhibition
of substrate efflux by cytochalasin B.

The transmembrane helical pairs 2/11 and 5/8 are predicted to
lie adjacent to one another and to form half of the inner bundle of
helices that form the outward-facing aqueous substrate-binding
cavity [30]. In order to further test this model and to detect
movements of inner transmembrane helices during ligand binding,
13 Glut1 mutants were constructed in which cysteine residues
were substituted into each pair of helices (see Table 1). All of the
paired cysteine substitutions were placed at positions predicted to
lie at roughly the same location along the axis perpendicular to the
plane of the membrane according to the original topological
model [7]. However, 9 of the 13 substitutions were chosen so that
the paired cysteine residues were predicted to lie directly across
from one another in their respective helices, whereas the other
four dicysteine mutants were made in paired residues predicted to
be positioned on opposite faces of their helices. We would thus
predict that at least some of the group of 9 dicysteine mutants
should be subjected to intramolecular chemical cross-linking via
their sulfhydryl groups, whereas none of the 4 control mutants
should be cross-linked.
Figure 1 shows an immunoblot demonstrating that all 13 dicysteine
mutants were efficiently expressed in Xenopus oocyte membranes.
The mutant proteins appeared as doublets and the relative intensity
of the two members of the doublet varied in some of the mutants
relative to the parental construct. Whether the doublet is the result of
the existence of distinct conformers of the proteins under the
conditions of SDS-PAGE or the presence of an unknown partial posttranslational modification is not known. However, the existence of the
doublets did not influence the results of the cross-linking experiments
described below, nor did the relative ratio of the doublet members
correlate with transport activity. All of the mutants exhibited 2deoxyglucose uptake activities in intact oocytes that were comparable
to the parental C-Tev control, except for A70C/M420C, which
showed a nearly 3-fold increase in transport activity (Figure 2).
Altered transport activity, either enhancement or inhibition, has been
Table 1. Construction of di-cysteine mutants in a C-Less
GLUT 1 reporter molecule.

A70C/M420C

Results
A reporter Glut1 molecule (C-TEV) was engineered in order to
facilitate the determination of the relative proximity and
orientation of pairs of transmembrane helices using chemical
cross-linking of di-cysteine (di-C) mutants, an experimental
approach that has been successfully used to analyze the structure
of many integral membrane proteins [37]. A TEV protease
recognition site was introduced into the large, central, cytoplasmic
loop of C-less Glut1 (Glut1 whose 6 native cysteine residues were
mutated to threonine or serine residues), permitting the analysis of
pairs of cysteine residues residing in opposite halves of the
molecule after chemical cross-linking. We have previously
demonstrated that C-less Glut1 exhibits close to wild-type
transport activity when expressed in Xenopus oocytes [35]. The
single site of N-linked glycosylation was also eliminated in the
reporter Glut1 construct in order to simplify quantification of the
data by preventing the smearing of the bands on SDS gels due to
heterogeneous glycosylation. The 2-deoxyglucose transport activity of the resultant C-TEV construct expressed in oocytes was
,40% of the activity of the parental C-less Glut1 protein (0.33
versus 0.82 pMoles/oocyte/30 min/unit protein expression).
PLoS ONE | www.plosone.org

Helix 2

Helix 11

GCCRTGC

ATGRTGC

V74C/T413C

GTTRTGT

ACCRTGC

G76C/N411C

GGCRTGC

AACRTGC

M77C/F409C

ATGRTGC

TTCRTGC

F81C/A405C

TTCRTGC

GCCRTGC

L85C/A402C

CTTRTGT

GCTRTGT

F86C/I404C

TTCRTGC

ATTRTGT

Helix 5

Helix 8

L156C/V327C

CTGRTGC

GTGRTGC

T158C/L325C

ACCRTGC

CTGRTGC

V165C/T321C

GTCRTGC

ACTRTGC

G172C/G314C

CAGRTGT

GGTRTGT

F174C/A309C

TTCRTGC

GCCRTGC

L176C/V307C

CTGRTGC

GTGRTGC

An aglyco Glut1 reporter molecule was created by mutating the consensus site
of N-linked glycosylation at N45 to a threonine residue and by inserting a Tev
protease cleavage site (ENLYFQG) between residues 247 and 248 in the central
cytoplasmic loop of Glut1. This reporter construct was then used to make the
above 13 dicysteine mutants in helices 2/11 and helices 5/8.
doi:10.1371/journal.pone.0031412.t001
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denoted as the cross-linking efficiencies in Table 2. Notably, none
of the 4 dicysteine mutants with substitutions at residues predicted
to lie on opposite faces of their respective helices exhibited crosslinking, whereas 5 of the 9 mutants with substitutions at residues
predicted to lie in direct apposition to one another were subject to
statistically significant levels of cross-linking by at least one of the
reagents. The highest levels of cross-linking were observed for
mutants A70C/M420C and F81C/A405C (helices 2/11) and
T158C/L325C (helices 5/8). Much weaker but statistically
significant levels of cross-linking were also observed for L85C/
I404C (helices 2/11) and Q172C/G314/C (helices 5/8). Each of
these 5 mutants was susceptible to cross-linking by o-PDM,
whereas only T158C/L325C and A70C/M420C were crosslinked by BMH. NEM had no effect on the protease cleavage of
any of the 13 mutants. Control experiments indicated that none of
the dicysteine mutants were subjected to inter-molecular crosslinking, as noted by the absence of oligomers when samples were
analyzed on non-reducing gels (data not shown). These data
indicate that these 5 sets of paired residues lie within ,6–16 Å of
each other at some point during the transport cycle.
Previous protease sensitivity experiments have suggested that
significant conformational changes accompany the binding of
ligands to Glut1 [39,40]. However, no studies have yet been
reported concerning movements that may occur in specific pairs of
transmembrane helices or paired amino acid residues of a glucose
transporter during the transport cycle or after ligand binding. In
order to determine whether helices 5/8 and 2/11 undergo relative
displacement after ligand binding, two inhibitors of glucose
transport were used. Cytochalasin B competitively inhibits sugar
efflux and non-competitively inhibits sugar uptake [41,42]. This
observation suggests that the binding of glucose at the endofacial
substrate-binding site and of cytochalasin B to its binding site on
Glut1 are mutually exclusive events, although it does not indicate
where on the Glut1 molecule cytochalasin B binds. Ethylidene
glucose is a non transported substrate analog that competitively
inhibits substrate influx, most likely by binding preferentially to the
exofacial binding site of Glut1 [43].

observed for many Glut1 point mutants (see [30] and references
therein). The results of preliminary experiments involving time
courses and concentration curves indicated that maximal crosslinking of dicysteine mutants was achieved when membranes were
incubated for 20 min in the presence of 1.0 mM BMH (bismaleimidehexane), a flexible sulfhydryl-specific cross-linker ,16 Å in
length, or 1.0 mM o-PDM (1,4-Phenylenedimaleimide), a relatively
rigid molecule ,6 Å in length [38] (data not shown). After the
20 min incubation period, cross-linking was quenched by the
addition of 5 mM cysteine, the membranes were digested with
TEV protease, and then subjected to immunoblot analysis. If the two
cysteine residues in a dicysteine mutant are in the proper orientation
and close enough to one another in proximity, the mutant transporter
should show pseudo-protease resistance proportional to the efficiency
of the cross-linking reaction. Figure 3 shows a representative series of
immunoblots obtained for all 13 mutants as well as the control
parental C-Tev construct. Cleavage of the full-length ,54 kD control
construct (C-Tev, upper panel), which lacks cysteine residues,
generated an N-terminal fragment of ,32 kDa (green bands) and a
C-terminal fragment of ,26 kDa (red bands). Cleavage was ,90%
efficient. Cross-linking of the mutants is indicated by a reduction in
the disappearance of the full-length ,54 kD bands along with a
corresponding decrease in the appearance of the N- and C-terminal
fragments relative to samples incubated with vehicle alone (lanes
labeled ‘‘DMSO’’) prior to protease cleavage. The DMSO lanes thus
provided an estimate of the maximum protease cleavage efficiency for
each mutant. Samples were also treated with 1.0 mM NEM to
determine whether modification of sulfhydryl groups alone in the
absence of cross-linking affected protease cleavage (lanes labeled
‘‘NEM’’). NEM did not affect the protease cleavage of any of the
dicysteine mutants.
Quantification of the results of 3–8 independent experiments is
presented in Table 2. The data are expressed as the intensity of the
full-length protein bands present in the protease-digested crosslinked samples (‘‘o-PDM’’, ‘‘BMH’’ lanes in Figure 3) divided by
the intensity of the full-length bands present in the undigested
control samples (‘‘Control’’ lanes in Figure 3). These values are

Figure 1. Expression of dicysteine mutants in Xenopus oocyte membranes. Stage 5 Xenopus oocytes were injected with water (Sham) or
with 50 ng of mRNA encoding the parental reporter construct (C-Tev) or the indicated dicysteine mutant. Two days post injection total oocyte
membranes were prepared and subjected to immunoblot analysis using a rabbit polyclonal ab raised against a peptide corresponding to the Cterminal 15 residues of human Glut1.
doi:10.1371/journal.pone.0031412.g001
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Figure 2. 2-Deoxyglucose uptake activity of Glut1 mutants.
[3H]-2-DOG uptake (50 mM, 30 min. at 22uC) was measured 2 days after
injection of oocytes with 50 ng of mRNA. Activities were normalized to
the value measured for oocytes expressing the control C-Tev construct
(0.1860.03 pMoles/oocyte/30 min/unit band intensity). Unit band
intensity refers to the relative intensity of the protein bands as
measured by immunoblot analysis using a Li-Cor imager and normalizes
for varying levels of protein expression for the different mutants.
Results represent the mean 6 SE of 3–6 independent experiments with
15–20 oocytes per experimental group. Values observed in waterinjected oocytes were subtracted.
doi:10.1371/journal.pone.0031412.g002

Figure 3. Chemical Cross-linking of di-C Mutants. Stage 5
Xenopus oocytes were injected with 50 ng of mRNA encoding the
parental reporter construct (C-Tev) or the indicated dicysteine mutants
(see Table 1). After incubation of oocytes for 2 days, cross-linking
analysis was conducted on purified oocyte membranes as described in
‘‘Materials and Methods’’. The reactions were quenched by the addition
of 2 mM cysteine and oocyte membranes were digested with Tev
protease then subjected to SDS-PAGE followed by immunoblotting
with rabbit polylclonal ab raised against the C-terminal 15 residues of
human Glut1 (red bands) and a mouse monoclonal ab that recognizes
an epitope in the N-terminal half of the central cytoplasmic loop (green
bands). Note that the full-length ,54 kD bands were recognized by
both antibodies and show up as yellow when the intensity of the
detector was increased. ‘‘C-TEV’’ is the control cysteine-less parental
construct. ‘‘Control’’ lanes were loaded with membranes that were not
subjected to either chemical cross-linking or protease cleavage.
‘‘DMSO’’ lanes were loaded with membranes that were not subjected
to chemical cross-linking but were digested with TEV protease. The ‘‘oPDM’’ and ‘‘BMH’’ lanes were loaded with membranes that were
subjected to cross-linking by the respective chemical and then were
treated with TEV protease. The ratio of the intensities of the full-length
bands in the DMSO lanes to those in the Control lanes thus provide the
maximum level of protease cleavage for each mutant. The ratio of the
intensities of the full-length bands in the ‘‘o-PDM’’ or ‘BMH’’ lanes to
those in the Control lanes indicate the extent of cross-linking by either
reagent. This ratio is termed the cross-linking efficiency or ‘‘fraction
cross-linked’’ in Table 2.
doi:10.1371/journal.pone.0031412.g003

Because the covalent cross-linking reactions would eventually
reach a plateau regardless of any competitive effect of the
reversible binding of the two transport inhibitors, early time points
were examined using lower concentrations of o-PDM and BMH in
order to observe whether the inhibitors had any effect on the crosslinking reactions. Concentrations and time points were based on
preliminary experiments for each mutant that maximized the
observed effects.
The effects of cytochalasin B and ethylidene glucose on the
kinetics of cross-linking of 3 of the 5 susceptible dicysteine mutants
are shown in Figure 4 and quantification of the results is presented
in Table 3. The cross-linking of L85C/A402C and Q172C/
G314C could not be accurately assessed by this analysis because of
their low levels of maximal cross-linking (5% and 8%, respectively,
PLoS ONE | www.plosone.org
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more than ,10 percent sequence identity with any of the 4
bacterial transporters of the MFS whose structures have been
deduced by x-ray diffraction, nor do they appear to share the
minimum 30 percent sequence identity with any known
prokaryotic proteins. Thus, other approaches to exploring the
structure of these proteins are required to make progress in this
area in the absence of x-ray diffraction data. Additionally,
alternate biochemical approaches to structure are usually
complementary to, and not precluded by, x-ray data.
The data presented in this study demonstrate that 5 of 13
dicysteine mutant Glut1 transporters were susceptible to intramolecular chemical cross-linking by homobifunctional, thiol-specific
cross-linking reagents. Cross-linking was observed between two
pairs of predicted inner transmembrane helices, 2/11 and 5/8.
The cross-linking data are consistent with a model for the structure
of Glut1 based on a comprehensive series of scanning mutagenesis
studies employing the substituted cysteine accessibility method
[21,22,23,24,26,27,28,29,30,31,32] as well as previous crosslinking studies [45] and with the overall protein folding pattern
observed for bacterial members of the MFS. All 5 of the
susceptible dicysteine mutants exhibited cross-linking by o-PDM
and 2 of the mutants were cross-linked by both o-PDM and BMH.
o-PDM and BMH have linkers that permit cross-linking distances
of up to ,6 Å and ,16 Å, respectively [38]. However, successful
cross-linking by a specific reagent also depends on the precise
spatial orientation and accessibility of the reactive groups. Crosslinking of both pairs of helices in the absence of ligand occurred at
residues predicted to lie near the exoplasmic and cytoplasmic faces
of the membrane, indicating that at some point or points during
the transport cycle one or both ends of these pairs of helices lie
within ,6 Å of each other, consistent with the close proximity
predicted by the 2-dimensional model shown in Figure 5. The
fractional cross-linking efficiency of 2 of the mutants (L85C/
A402C, Q172C/G314C) was very low, although still statistically
significant. Whether this low efficiency was due to steric and
geometrical constraints, the accessibility of the homobifunctional
reagents to these sulfhydryl groups, or to some other factor, cannot
be determined at present.
The cross-linking of 3 of the mutants allowed us to evaluate the
effect of non-transported ligands on cross-linking behavior and to
draw inferences concerning the basic conformational states
induced by these inhibitors. Cytochalasin B, a mold metabolite,
is one of the most potent low molecular weight inhibitors of Glut1
activity that has been reported [46]. Several different observations
have led to the assumption that cytochalasin B binds to the
endofacial conformation of the transporter, possibly overlapping
the substrate-binding site, and thus inhibiting activity: First,
cytochalasin B is a competitive inhibitor of substrate efflux and a
non-competitive inhibitor of substrate influx [41]. Second,
homology modeling of Glut1 structure suggested a cytoplasmic
docking site for cytochalasin B [47]. Third, the kinetics of
dissociation of the cytochalasin B/Glut1 complex stimulated by an
exofacial ligand are consistent with cytochalasin B binding to the
endofacial conformation [48]. Fourth, modeling studies suggest
that cytochalasin B may bind to a substrate-binding site of the
transporter via hydrogen bonds and hydrophobic interactions
analogous to those that occur between glucose and Glut1 [49].
These observations strongly support the view that cytochalasin B
binds to Glut1 in its endofacial configuration, but do not provide
direct evidence as to the sidedness or precise location of
cytochalasin B binding on Glut1. Mutagenesis experiments
indicate that W388 and W412 are involved in the Glut1/
cytochalasin B interaction [50,51], and protease digestion
experiments suggest that photolabeling of Glut1 by cytochalasin

Table 2. Cross-linking Efficiency of Glut1 Dicysteine Mutants.

Fraction Cross-Linked
Double
Mutant

1.0 mM
o-PDM

1.0 mM BMH

Average SE

n

p value Average SE

n

p value

Helices 2/11
A70C/M420C

0.266

0.098

5

0.001

0.056

0.032

5

0.169

V74C/T413C

20.070

0.029

3

0.071

20.054

0.025

3

0.096

G76C/N411C

20.109

0.072

3

0.204

20.221

0.130

3

0.163

M77C/F409C

20.047

0.048

3

0.387

20.060

0.040

3

0.208

F81C/A405C

0.307

0.100

5

0.001

20.004

0.037

5

0.488

L85C/A402C

0.080

0.029

5

0.002

0.094

0.035

5

0.005

F86C/I404C

0.006

0.050

3

0.911

0.029

0.081

3

0.741

Helices 5/8
L156C/V327C

20.036

0.016

4

0.039

20.071

0.028

5

0.033

T158C/L325C

0.750

0.112

6

0.001

0.464

0.065

7

0.001

V165C/T321C

20.025

0.014

7

0.073

20.013

0.017

8

0.445

G172C/G314C

0.050

0.019

6

0.019

0.019

0.045

7

0.703

F174C/A309C

0.011

0.025

4

0.670

20.057

0.023

5

0.065

L176C/V307C

20.018

0.040

4

0.669

20.027

0.029

5

0.433

Oocyte membranes expressing dicysteine mutants were subjected to chemical
cross-linking as described in Materials and Methods. Cross-linking efficiency is
expressed as the intensity of the full-length transporter bands in the crosslinked lanes (o-PDM and BMH lanes, see Figure 3) divided by the intensity of the
full-length transporter bands in the control lanes, after subtraction of
background intensities. See Figure 3 for a representative set of immunoblots.
The results of 3–8 independent experiments are presented.
doi:10.1371/journal.pone.0031412.t002

see Table 2). Neither cytochalasin B nor ethylidene glucose had
any significant affect on the cross-linking of F81C/A405C
(Figures 4A and B). Interestingly, however, cytochalasin B
stimulated the cross-linking of T158C/L325C by o-PDM by 1.8
fold (P = 0.02) but had no affect on cross-linking by BMH
(Figures 4C and D). Ethylidene glucose had no effect on either
cross-linking reaction. In contrast, ethylidene glucose enhanced
the cross-linking of A70C/M20C by BMH by 10-fold (P = 0.03),
whereas cytochalasin B had no significant affect on cross-linking
(Figure 4E and F). Ethylidene glucose also stimulated the crosslinking of A70C/M420C by o-PDM by 2-fold, but this effect was
not statistically significant. These data demonstrate that the
binding of a non-transported substrate analog to the exofacial
binding site or the binding of a competitive inhibitor of substrate
efflux induce conformational changes in Glut1 that result in the
relative movements of the inner helical pairs 2/11 or 5/8,
respectively. T158C/L325C has cysteine substitutions at the
cytoplasmic ends of helices 5 and 8, whereas A70C/M20C has
cysteine substitutions at the exoplasmic ends of helices 2 and 11
(see Figures 5 and 6). Thus, these results indicate that cytochalasin
B recruits Glut1 to a conformational state whereby the cytoplasmic
ends of helices 5 and 8 move closer together, and that ethylidene
glucose promotes a conformational state in which the exoplasmic
ends of helices 2 and 11 move closer together.

Discussion
A minimum of 30 percent sequence identity is required in order
to accurately model a membrane protein structure based on
homology [44]. Mammalian glucose transporters do not share
PLoS ONE | www.plosone.org
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Figure 4. Effect of non-transported ligands on chemical cross-linking. Oocyte membranes were incubated in presence of either vehicle
alone (water or ethanol) or 50 mM cytochalasin B or 50 mM ethylidene glucose for 5 min prior to the addition of the indicated concentration of either
o-PDM or BMH. Cross-linking efficiency was measured by protease cleavage followed by immunoblot analysis as described in ‘‘Materials and
Methods’’. The water lanes represent the controls for the addition of ethylidene glucose and the ethanol lanes controlled for the addition of
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cytochalasin B. The DMSO lanes represent samples to which DMSO was added but no cross-linker. These lanes indicate the maximum cleavage
observed for each mutant with TEV protease.
doi:10.1371/journal.pone.0031412.g004

B involves a ,3 kD region encompassing these two tryptophan
residues [52].
In the present study cytochalasin B stimulated the cross-linking
of residues T158C and L325C. These residues are predicted to lie
near the cytoplasmic ends of helices 5 and 8, respectively (see
Figure 6). This indicates that cytochalasin B binding decreases the
distance between these two residues and suggests that cytochalasin
B binding promotes closure of the helical bundle near the
cytoplasmic face of the membrane. Recent evidence suggests that
Glut1 may possess distinct high and low affinity binding sites for
cytochalasin B [42]. When the higher affinity site is occupied,
transport activity is stimulated, but the occupation of the lower
affinity site at higher ligand concentrations results in transport
inhibition. Cytochalasin B was present at saturating inhibitory
concentrations during the cross-linking reactions. We speculate
that cytochalasin B-induced closure of helices near the cytoplasmic

face of the membrane prevents access of glucose to the endofacial
substrate-binding site, which would be observed as competitive
inhibition of substrate efflux [41,53,54]. Cytochalasin B might
induce closure of the helices by binding to the endofacial substratebinding site or to an allosteric binding site on the Glut1 molecule.
The only requirement is that the binding promotes a structural
change in Glut1 that induces sufficient closure of the endofacial
cavity to prevent access to the substrate-binding site, and binding
must occur to Glut1 in the endofacial conformation. The present
data do not have any implications as to whether cytochalasin B
binds to an exofacial region, endofacial region, or intramembranous domain of Glut1.
4,6-O-ethylidene glucose is a Glut1 substrate analog that
appears to bind to the exofacial substrate binding site with ,10fold greater apparent affinity compared to the endofacial site
[41,43,54]. The presence of high concentrations of this modified

Figure 5. Cross-sectional model of the inner transmembrane helices of Glut1 in the exoplasmic conformation as viewed from the
exoplasmic face of the membrane based on experimental results. Amino acid residues subjected to cysteine substitution in the dicysteine
mutants are given by the single letter code. Red lines connect residues that were cross-linked by o-PDM or BMH within the helical pairs 2/11 and 5/8.
doi:10.1371/journal.pone.0031412.g005
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data it might be predicted that ethylidene glucose would, at least
initially, recruit Glut1 molecules to the outward configuration with
the inner transmembrane helices spread apart at the exoplasmic
side of the membrane. In apparent contradiction to this
prediction, our data indicate that the presence of ethylidene
glucose dramatically enhanced the cross-linking of residues A70C
and M420C in a dicysteine mutant by up to ,20-fold (see
Figure 4), suggesting that binding of the sugar analog to the
exofacial site causes helices 2 and 11 to pinch together. The
simplest interpretation of these data is that after the initial binding
of ethylidene glucose to the exofacial site, the transporter
undergoes a conformational change in which the exoplasmic ends
of the inner helices close around the bound ligand, thus decreasing
the average distance between residues A70C and M420C and
increasing the degree of cross-linking. The bulky ethylidene group
between C-4 and C-6 may prevent the full conversation of the
transporter to the endofacial configuration, so that the transporter
is transiently present in an intermediate conformation before the
complex relaxes back to the exofacial configuration followed by
release of the bound ligand. Alternatively, the transporter may
fully convert to the exofacial conformation but fail to release the
ligand because of the ethylidene moiety.
An alternative interpretation for the closure of helices 5 and 8 or
helices 2 and 11 after cytochalasin B or ethylidene glucose binding,
respectively, is that the pinching together of these helices is
required for the opening of other inner transmembrane helices
that is in turn required to allow access to the cytoplasmic or
exoplasmic substrate binding site.
The results of the cross-linking experiments reported herein are
completely consistent with the low resolution 2-dimensional model
of the relative orientation of the inner transmembrane helices in
the Glut1 exofacial conformation deduced from a comprehensive
series of mutagenesis and solvent accessibility experiments
(summarized in [30], see Figure 5). Thus, all of the observed
cross-linking may in theory have occurred with Glut1 in the open
exofacial conformation or in an alternative conformation where
the relative positions of the cross-linked residues do not differ
significantly from that in the exofacial conformation. In an attempt
to assess the possibility that one or more cross-linking events may
have occurred with Glut1 in the endofacial conformation, we
examined the orientation and distance between cross-linked
residues in a homology-based model of Glut1 [47] (see Figure 6).
The distance between the cross-linked residues in the model varies
from ,9 to ,21 Å. Given that all five cross-linking events were
observed with o-PDM, which allows a maximum distance of
6–8 Å between residues [38], it appears that either none of the
cross-links occurred in the endofacial configuration of the
transporter, or alternatively, the model is not accurate. The ability
of cytochalasin B to enhance the cross-linking of T158C and
L325C strongly suggests that this event occurred with the
transporter in the endofacial configuration (see the above
discussion). This implies that the homology-based model is not
accurate with respect to the orientation of helices 5 and 8. It
should be mentioned that the glycerol-3-P antiporter used as the
template in the homology modeling shares little if any sequence
identity with Glut1, and that a minimum of ,30% identity is
required between two proteins for accurate homology-based
modeling [44].
The data presented in the study provide evidence that the
binding of non-transported ligands to Glut1 promotes movements
of inner transmembrane helices and support an alternating
conformation-type transport mechanism [55], consistent with the
comparative structures of bacterial MFS proteins. However,
elucidation of the glucose transport mechanism ultimately is

Figure 6. Side-view of the orientation of helices 2/11 and 5/8 of
Glut1 in the endofacial conformation based on homology
modeling. The orientation of the helices is derived from an homologybased model of Glut1 that used the structure of the E. coli Glycerol-3-P
Antiporter as the template molecule [17]. Side chains of residues that
were mutated to cysteines and subjected to chemical cross-linking
analysis are identified by their single letter amino acid codes. Residues
that exhibited cross-linking are shown in green in ball and stick form
and are connected by dotted lines. Distances between cross-linked
residues are given in angstroms (Å). Residues that did not exhibit crosslinking are shown in red.
doi:10.1371/journal.pone.0031412.g006

sugar should thus initially recruit Glut1 to the exofacial
conformation. An interesting question is what happens after this
non-transported ligand binds to the exofacial site? Crystal
structures of MFS proteins in the endofacial [15,17] and exofacial
[16] conformations reveal that inner transmembrane helices splay
open to allow access to a substrate binding site at one side of the
membrane and pinch together at the opposite side of the
membrane to seal off the aqueous cavity. From these diffraction
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Table 3. Effect of Ligands on the Cross-Linking of Glut1 Di-cysteine Mutants.

Double Mutant

0.1 mM o-PDM

0.1 mM BMH

Average

SE

n

0.347

0.104

4

p value

Average

SE

n

0.099

0.090

4

20.002

0.050

4

20.027

0.037

4

0.002

0.054

4

0.609

0.175

4

0.804

0.230

4

0.697

0.114

4

0.632

0.106

4

0.001

0.069

4

20.076

0.040

4

0.017

0.038

4

0.199

0.048

4

p value

F81C/A405C
ETOH
CB

0.440

0.143

4

Water

0.334

0.102

4

EG

0.320

0.085

4

T158C/L325C

0.3 mM o-PDM

ETOH

0.273

0.041

5

CB

0.489

0.062

5

Water

0.448

0.081

5

EG

0.437

0.100

5

A70C/M420C

0.1 mM o-PDM

ETOH

0.048

0.059

4

CB

0.037

0.070

4

Water

0.118

0.044

4

EG

0.270

0.079

4

0.620

0.917

0.336

0.674

0.3 mM BMH

0.019

0.938

0.556

0.784

0.1 mM BMH

0.916

0.143

0.373

0.026

Oocyte membranes expressing dicysteine mutants were subjected to chemical cross-linking as described in Materials and Methods in the presence or absence of
cytochalasin B (CB) or ethylidene glucose (EG). Cross-linking efficiency is expressed as the intensity of the full-length transporter bands in the cross-linked lanes (o-PDM
and BMH lanes, see Figure 4) divided by the intensity of the full-length transporter bands in the control lanes, after subtraction of background intensities. See Figure 4
for a representative set of immunoblots. The results of 4–5 independent experiments are presented. Ethanol (ETOH) is the control for the addition of cytochalasin B (CB),
and Water is the control for the addition of ethylidene glucose (EG).
doi:10.1371/journal.pone.0031412.t003

dependent on the crystallization of the transporter in multiple
configurations in the presence and absence of substrate.

Construction of di-Cysteine Glut1 Mutants
C-less Glut1 cDNA [23,56] subcloned into the oocyte
expression vector pSP64T was subjected to site-directed mutagenesis to produce an aglyco C-less Glut1 containing the amino
acid motif for a Tev protease cleavage site(Glu-Asn-Leu-Tyr-PheGln-Gly) within the large, central cytoplasmic loop between
residues Gly247 and S248. The site of N-linked glycosylation was
mutated (Asn45 to Ser) in order to simplify quantification of the
protein bands (see Table 1). This construct, designated C-Tev, was
then used as a template to create 13 di-cysteine mutants in the
helical pairs 5/8 and 2/11 (see Table 1). The cysteine substitutions
were generated extending from the inner face to the outer face of
the membrane in each of the helices.

Materials and Methods
Ethics Statement
All experiments involving Xenopus frogs were conducted with
the approval of the Washington University Animal Studies
Committee (Protocol #200110049).

Materials
Xenopus laevis –Imported African frogs were purchased from
Xenopus Express (Homosassa, FL), 3H-2-deoxyglucose and
Diguanosine triphosphate (mRNA cap) were purchased from
Amersham Pharmacia Biotech (Arlington Heights, IL), MegascriptTM RNA synthesis kit was purchased from Ambion Inc
(Austin, TX), TransformerTM Site-Directed mutagenesis kit was
obtained from Clontech (Palo Alto, CA). SuperSignal TM West
Pico Chemiluminiscent Substrate and Bismaleimidehexane (BMH)
were obtained from Pierce (Rockford, IL), 1,4-Phenylenedimaleimide (o-PDM) was purchased from Aldrich Chemical Co.
(Milwaukee, WI), and Decylmaltoside (DM) was obtained from
Anatrace Inc. (Maumee, OH).

Treatment with homobifunctional maleimide crosslinking reagents and effect of transport inhibitors
Stage 5 Xenopus oocytes were injected with 50 ng of each mutant
Glut1 mRNA. Two days after injection, total membranes were
prepared from groups of 15–20 oocytes. Three micrograms of
freshly isolated total membranes from injected oocytes were
incubated with the indicated concentrations of o-PDM, BMH, or
NEM in 50 mM Tris-HCl pH 7.4, 0.5 mM EDTA, 1 mM
dithiothreitol for various time periods at 22uC. In the inhibitor
experiments either cytochalasin B (50 mM) or ethylidene glucose
(50 mM) were added to the samples 5 min prior to the addition of
the cross-linking reagents. Control experiments demonstrated that
up to 50 mM L-glucose had no effect on the cross-linking reactions
(data not shown). The reaction was quenched by the addition of
2 mM cysteine and the membranes were then treated with 10
units of TEV protease (In Vitrogen) for 1 h at 22uC. The digested
membranes were then analyzed by SDS PAGE and immunoblot
analysis using a rabbit polyclonal ab raised against a peptide

General Procedures
Procedures for the site-directed mutagenesis and sequencing of
human Glut1 cDNA and the in vitro transcription and purification
of Glut1 mRNAs (25), isolation, microinjection, and incubation of
Xenopus oocytes (26), preparation of oocyte membranes (23), SDS
polyacrylamide gel electrophoresis and immunoblotting with
Glut1 C-terminal antibody (20), and 2-deoxyglucose uptake
measurements (27), have been described in detail previously.
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corresponding to the C-terminal 15 residues of human Glut1
(1:10,000 dilution) and a mouse monoclonal ab that recognizes a
motif within the N-terminal half of the central cytoplasmic loop
(1:10,000 dilution of ascites fluid). The secondary abs used were
LiCor donkey anti-mouse IRDye 800 CW and donkey anti-rabbit
IRDye 680 (both at 1:10,000 dilution) in conjunction with
LiCor blocking buffer. Imaging of the blots was conducted using
a LiCor Odyssey infrared imaging system model 9120 and system
version 3.0.

Statistical Analysis
Data were analyzed for statistical significance using the twotailed, unpaired, Student’s T-test.

Author Contributions
Conceived and designed the experiments: MM CM. Performed the
experiments: MM CM. Analyzed the data: MM CM. Contributed
reagents/materials/analysis tools: MM CM. Wrote the paper: MM CM.
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